Spots Global Cancer Trial Database for skb264
Every month we try and update this database with for skb264 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | NCT06279364 | Triple Negative... | SKB264 Paclitaxel Nab-paclitaxel Capecitabine Eribulin Carboplatin | 18 Years - 75 Years | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | |
| SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer | NCT05347134 | Triple Negative... | SKB264 | 18 Years - 75 Years | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | |
| A Phase III Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | NCT06081959 | Metastatic Brea... | SKB264 Eribulin Capecitabine Gemcitabine Vinorelbine | 18 Years - 75 Years | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | |
| A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients | NCT05870319 | Non-small Cell ... | SKB264 Pemetrexed Carboplatin Cisplatin | 18 Years - 75 Years | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | |
| A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | NCT05816252 | Non-small Cell ... | SKB264 Pembrolizumab Carboplatin Osimertinib | 18 Years - | Klus Pharma Inc. | |
| Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies | NCT04152499 | Epithelial Ovar... Gastric Adenoca... Gastroesophagea... Urothelial Carc... Non-Small Cell ... Small-Cell Lung... Endometrial Car... Head and Neck S... Breast Cancer | SKB264 | 18 Years - 75 Years | Klus Pharma Inc. | |
| SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors | NCT05642780 | Solid Tumor | SKB264 Pembrolizumab | 18 Years - | Klus Pharma Inc. | |
| SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. | NCT05351788 | Non-small Cell ... | SKB264 KL-A167 Carboplatin Cisplatin | 18 Years - 75 Years | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | |
| A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients | NCT05870319 | Non-small Cell ... | SKB264 Pemetrexed Carboplatin Cisplatin | 18 Years - 75 Years | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | |
| SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors | NCT05631262 | Selected Subjec... | SKB264 Docetaxel | 18 Years - 75 Years | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | |
| A Phase III Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | NCT06081959 | Metastatic Brea... | SKB264 Eribulin Capecitabine Gemcitabine Vinorelbine | 18 Years - 75 Years | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | |
| SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors | NCT05642780 | Solid Tumor | SKB264 Pembrolizumab | 18 Years - | Klus Pharma Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
